Assembly Biosciences Q1 Revenue Falls, Net Loss Widens to $9.08M
Summary
Assembly Biosciences reported a decline in Q1 revenue and a widened net loss of $9.08 million, or -$0.54 per share. The revenue decrease was primarily attributed to the timing of activities under its collaboration with Gilead Sciences. This financial performance represents a negative shift from the significantly reduced net loss reported for the full year 2025. While the company completed Phase 1b studies for its herpes and hepatitis delta virus candidates, the widened loss could raise concerns. Traders will be watching for the mid-2026 decision on the Gilead herpesvirus program opt-in and the planned Q4 2026 initiation of a Phase 2 study for ABI-6250 as potential future catalysts.
At the time of this announcement, ASMB was trading at $30.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $491.6M. The 52-week trading range was $11.64 to $39.71. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.